muscular atrophy/bolest hlavy

Odkaz je uložen do schránky

Vyberte typ řazení

15 Výsledek

Administration of nusinersen via paramedian approach for spinal muscular atrophy

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Objective: To assess the success rate, procedure time, and adverse events of intrathecal administration of nusinersen via the paramedian approach in adolescents and adults with spinal muscular atrophy (SMA) associated with

Simple Fluoroscopy-Guided Transforaminal Lumbar Puncture: Safety and Effectiveness of a Coaxial Curved-Needle Technique in Patients with Spinal Muscular Atrophy and Complex Spines.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Patients with spinal muscular atrophy often have complete interlaminar osseous fusion, precluding lumbar puncture via the standard interlaminar approach. Recently, we have developed a new coaxial curved-needle variation of fluoroscopy-guided transforaminal lumbar puncture for intrathecal injections

Nusinersen: A Treatment for Spinal Muscular Atrophy.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE To review the efficacy and safety of nusinersen (Spinraza) in the treatment of spinal muscular atrophy (SMA). METHODS An English-language literature search of PubMed and MEDLINE (1946 to June 2018) was performed using the terms nusinersen, ISIS-SMN (Rx), and spinal muscular atrophy.

Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Patients' perceptions of benefit-risk are essential to informing the regulatory process and the context in which potential therapies are evaluated. To bring this critical information to regulators, Cure SMA launched a first-ever Benefit-Risk Survey for spinal muscular atrophy (SMA) to

Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Nusinersen, the only treatment approved by the United States Food and Drug Administration for spinal muscular atrophy (SMA), is delivered intrathecally. Many children with SMA have extensive spinal instrumentation and deformities, often precluding the use of standard approaches for gaining

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Treatment with nusinersen has demonstrated significant and clinically meaningful benefits in clinical trials in infants and children with spinal muscular atrophy (SMA).The objective of this analysis was to characterize the safety of nusinersen across the

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Nusinersen (ISIS-SMNRx or ISIS 396443) is an antisense oligonucleotide drug administered intrathecally to treat spinal muscular atrophy. We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension. During the

Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Nusinersen is approved for the treatment of 5q spinal muscular atrophy of all types and stages in patients of all ages. Although clinical trials have shown improvements in motor function in infants and children treated with the drug, data for adults are scarce. We aimed to assess the

Ultrasound-guided cervical puncture for nusinersen administration in adolescents.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Spinal muscular atrophy (SMA) is an autosomal-recessive disease affecting motor neurons and is the most common genetic cause of death in infants. Intrathecal nusinersen is the only therapy approved by the U.S. Food and Drug Administration for SMA. Deformities and spinal instrumentation

[Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) associated with hypothalamo-pituitary hypofunction--a case report].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

A case of 25-year-old woman with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) was reported. She had short stature, episodic vomiting with headache, several episodes with homonymous hemianopsia, progressive intellectual decline, generalized convulsion, muscular

Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

The Toxic Syndrome (TS) caused by ingestion of adulterated rapeseed oil in Spain is a new disease of multisystemic character whose aetiology and pathogenesis remains unknown. The most prominent pathological feature is a peculiar non-necrotizing vasculitis, that affects mainly the intima and involves

CPEO and carnitine deficiency overlapping in MELAS syndrome.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Mitochondrial myopathy, encephalopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome is one of the mitochondrial encephalomyopathies that has distinct clinical features including stroke-like episodes with migraine-like headache, nausea, vomiting, encephalopathy and lactic acidosis.

Nusinersen for older patients with SMA: a real-world clinical setting experience.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Clinical trials data concerning use of nusinersen in older spinal muscular atrophy (SMA) patients is lacking. We describe our center's experience in using intrathecal nusinersen for older patients in the clinical setting.Retrospective

Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease caused by loss of the SMN1 gene. Based on randomized clinical trials in children with SMA type 1 and 2, Nusinersen has been approved as the first treatment for all types of SMA, including adults

A community survey of neurological disorders in Saudi Arabia: the Thugbah study.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

We report the findings of a total population survey of Thugbah community in the Eastern Province of Saudi Arabia (SA) to determine its point prevalence of neurological diseases. During this two-phase door-to-door study, all Saudi nationals living in Thugbah were first screened by trained

Připojte se k naší
facebookové stránce

Herbal & Natural Medicine

Nejúplnější databáze léčivých bylin podložená vědou

Funguje v 55 jazycích
Bylinné léky podporované vědou
Rozpoznávání bylin podle obrázku
Interaktivní mapa GPS - označte byliny na místě (již brzy)
Přečtěte si vědecké publikace související s vaším hledáním
Hledejte léčivé byliny podle jejich účinků
Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu